Changes in use of antiretroviral therapy in regions of Europe over time

Ole Kirk, Amanda Mocroft, Terese L. Katzenstein, Adriano Lazzarin, Francisco Antunes, Patrick Francioli, Ray P. Brettle, Jacqueline M. Parkin, Juan Gonzales-Lahoz, D. Jens

Research output: Contribution to journalArticle

Abstract

Objectives: To analyse use of antiretroviral therapy within Europe between 1994 and 1997. Design: From September 1994, the EuroSIDA study (cohorts I-III) has prospectively followed unselected HIV-infected patients from 50 clinical centres in 17 European countries (total, 7230). Methods: Patients under follow-up at half-year intervals from September 1994 (n = 2871) to September 1997 (n = 3682) were classified according to number of drugs currently used (none, one, two, three, foul or more). Use of antiretroviral therapy was stratified by CD4 cell count (<200 versus ≥ 200 x 106/l) and by region of Europe (south, central, or north). Frequency data were compared by χ2 test and logistic regression modelling. Results: The proportion of patients on antiretroviral monotherapy diminished over time (1994, 42%; 1997, 3%), as did the proportion of patients without therapy (from 37 to 9%). Over time, the proportion of patients on triple (from 2 to 55%) and quadruple (from 0 to 9%) therapy increased, whereas use of dual therapy peaked in 1996 and subsequently fell. In the three regions of Europe, changes in use of antiretroviral therapy differed substantially. However, as of September 1997, only minor differences persisted. The proportion of patients on dual, triple, and quadruple therapy were as follow: south, 33, 52 and 5%, respectively; central, 23, 55 and 14%, respectively; north, 16, 59 and 10%, respectively. In September 1997, odds for use of three or more drugs including at least one protease inhibitor did not differ significantly between regions. Conclusions: Use of antiretroviral therapy in Europe has changed dramatically towards combination treatment in the last few years. Regional differences in use of antiretroviral therapy have decreased, and by September 1997 only minor differences remained. Antiretroviral therapy with three or more drugs and use of protease inhibitors has become more common in all regions of Europe.

Original languageEnglish
Pages (from-to)2031-2039
Number of pages9
JournalAIDS (London, England)
Volume12
Issue number15
Publication statusPublished - Oct 22 1998

Fingerprint

Therapeutics
Protease Inhibitors
Pharmaceutical Preparations
CD4 Lymphocyte Count
Cohort Studies
Logistic Models
HIV

Keywords

  • Combination therapy
  • Components of combination therapy
  • HIV infection
  • Protease inhibitor
  • Regional differences in Europe

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Kirk, O., Mocroft, A., Katzenstein, T. L., Lazzarin, A., Antunes, F., Francioli, P., ... Jens, D. (1998). Changes in use of antiretroviral therapy in regions of Europe over time. AIDS (London, England), 12(15), 2031-2039.

Changes in use of antiretroviral therapy in regions of Europe over time. / Kirk, Ole; Mocroft, Amanda; Katzenstein, Terese L.; Lazzarin, Adriano; Antunes, Francisco; Francioli, Patrick; Brettle, Ray P.; Parkin, Jacqueline M.; Gonzales-Lahoz, Juan; Jens, D.

In: AIDS (London, England), Vol. 12, No. 15, 22.10.1998, p. 2031-2039.

Research output: Contribution to journalArticle

Kirk, O, Mocroft, A, Katzenstein, TL, Lazzarin, A, Antunes, F, Francioli, P, Brettle, RP, Parkin, JM, Gonzales-Lahoz, J & Jens, D 1998, 'Changes in use of antiretroviral therapy in regions of Europe over time', AIDS (London, England), vol. 12, no. 15, pp. 2031-2039.
Kirk O, Mocroft A, Katzenstein TL, Lazzarin A, Antunes F, Francioli P et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS (London, England). 1998 Oct 22;12(15):2031-2039.
Kirk, Ole ; Mocroft, Amanda ; Katzenstein, Terese L. ; Lazzarin, Adriano ; Antunes, Francisco ; Francioli, Patrick ; Brettle, Ray P. ; Parkin, Jacqueline M. ; Gonzales-Lahoz, Juan ; Jens, D. / Changes in use of antiretroviral therapy in regions of Europe over time. In: AIDS (London, England). 1998 ; Vol. 12, No. 15. pp. 2031-2039.
@article{cce9866007014617b43b9623afe433e8,
title = "Changes in use of antiretroviral therapy in regions of Europe over time",
abstract = "Objectives: To analyse use of antiretroviral therapy within Europe between 1994 and 1997. Design: From September 1994, the EuroSIDA study (cohorts I-III) has prospectively followed unselected HIV-infected patients from 50 clinical centres in 17 European countries (total, 7230). Methods: Patients under follow-up at half-year intervals from September 1994 (n = 2871) to September 1997 (n = 3682) were classified according to number of drugs currently used (none, one, two, three, foul or more). Use of antiretroviral therapy was stratified by CD4 cell count (<200 versus ≥ 200 x 106/l) and by region of Europe (south, central, or north). Frequency data were compared by χ2 test and logistic regression modelling. Results: The proportion of patients on antiretroviral monotherapy diminished over time (1994, 42{\%}; 1997, 3{\%}), as did the proportion of patients without therapy (from 37 to 9{\%}). Over time, the proportion of patients on triple (from 2 to 55{\%}) and quadruple (from 0 to 9{\%}) therapy increased, whereas use of dual therapy peaked in 1996 and subsequently fell. In the three regions of Europe, changes in use of antiretroviral therapy differed substantially. However, as of September 1997, only minor differences persisted. The proportion of patients on dual, triple, and quadruple therapy were as follow: south, 33, 52 and 5{\%}, respectively; central, 23, 55 and 14{\%}, respectively; north, 16, 59 and 10{\%}, respectively. In September 1997, odds for use of three or more drugs including at least one protease inhibitor did not differ significantly between regions. Conclusions: Use of antiretroviral therapy in Europe has changed dramatically towards combination treatment in the last few years. Regional differences in use of antiretroviral therapy have decreased, and by September 1997 only minor differences remained. Antiretroviral therapy with three or more drugs and use of protease inhibitors has become more common in all regions of Europe.",
keywords = "Combination therapy, Components of combination therapy, HIV infection, Protease inhibitor, Regional differences in Europe",
author = "Ole Kirk and Amanda Mocroft and Katzenstein, {Terese L.} and Adriano Lazzarin and Francisco Antunes and Patrick Francioli and Brettle, {Ray P.} and Parkin, {Jacqueline M.} and Juan Gonzales-Lahoz and D. Jens",
year = "1998",
month = "10",
day = "22",
language = "English",
volume = "12",
pages = "2031--2039",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "15",

}

TY - JOUR

T1 - Changes in use of antiretroviral therapy in regions of Europe over time

AU - Kirk, Ole

AU - Mocroft, Amanda

AU - Katzenstein, Terese L.

AU - Lazzarin, Adriano

AU - Antunes, Francisco

AU - Francioli, Patrick

AU - Brettle, Ray P.

AU - Parkin, Jacqueline M.

AU - Gonzales-Lahoz, Juan

AU - Jens, D.

PY - 1998/10/22

Y1 - 1998/10/22

N2 - Objectives: To analyse use of antiretroviral therapy within Europe between 1994 and 1997. Design: From September 1994, the EuroSIDA study (cohorts I-III) has prospectively followed unselected HIV-infected patients from 50 clinical centres in 17 European countries (total, 7230). Methods: Patients under follow-up at half-year intervals from September 1994 (n = 2871) to September 1997 (n = 3682) were classified according to number of drugs currently used (none, one, two, three, foul or more). Use of antiretroviral therapy was stratified by CD4 cell count (<200 versus ≥ 200 x 106/l) and by region of Europe (south, central, or north). Frequency data were compared by χ2 test and logistic regression modelling. Results: The proportion of patients on antiretroviral monotherapy diminished over time (1994, 42%; 1997, 3%), as did the proportion of patients without therapy (from 37 to 9%). Over time, the proportion of patients on triple (from 2 to 55%) and quadruple (from 0 to 9%) therapy increased, whereas use of dual therapy peaked in 1996 and subsequently fell. In the three regions of Europe, changes in use of antiretroviral therapy differed substantially. However, as of September 1997, only minor differences persisted. The proportion of patients on dual, triple, and quadruple therapy were as follow: south, 33, 52 and 5%, respectively; central, 23, 55 and 14%, respectively; north, 16, 59 and 10%, respectively. In September 1997, odds for use of three or more drugs including at least one protease inhibitor did not differ significantly between regions. Conclusions: Use of antiretroviral therapy in Europe has changed dramatically towards combination treatment in the last few years. Regional differences in use of antiretroviral therapy have decreased, and by September 1997 only minor differences remained. Antiretroviral therapy with three or more drugs and use of protease inhibitors has become more common in all regions of Europe.

AB - Objectives: To analyse use of antiretroviral therapy within Europe between 1994 and 1997. Design: From September 1994, the EuroSIDA study (cohorts I-III) has prospectively followed unselected HIV-infected patients from 50 clinical centres in 17 European countries (total, 7230). Methods: Patients under follow-up at half-year intervals from September 1994 (n = 2871) to September 1997 (n = 3682) were classified according to number of drugs currently used (none, one, two, three, foul or more). Use of antiretroviral therapy was stratified by CD4 cell count (<200 versus ≥ 200 x 106/l) and by region of Europe (south, central, or north). Frequency data were compared by χ2 test and logistic regression modelling. Results: The proportion of patients on antiretroviral monotherapy diminished over time (1994, 42%; 1997, 3%), as did the proportion of patients without therapy (from 37 to 9%). Over time, the proportion of patients on triple (from 2 to 55%) and quadruple (from 0 to 9%) therapy increased, whereas use of dual therapy peaked in 1996 and subsequently fell. In the three regions of Europe, changes in use of antiretroviral therapy differed substantially. However, as of September 1997, only minor differences persisted. The proportion of patients on dual, triple, and quadruple therapy were as follow: south, 33, 52 and 5%, respectively; central, 23, 55 and 14%, respectively; north, 16, 59 and 10%, respectively. In September 1997, odds for use of three or more drugs including at least one protease inhibitor did not differ significantly between regions. Conclusions: Use of antiretroviral therapy in Europe has changed dramatically towards combination treatment in the last few years. Regional differences in use of antiretroviral therapy have decreased, and by September 1997 only minor differences remained. Antiretroviral therapy with three or more drugs and use of protease inhibitors has become more common in all regions of Europe.

KW - Combination therapy

KW - Components of combination therapy

KW - HIV infection

KW - Protease inhibitor

KW - Regional differences in Europe

UR - http://www.scopus.com/inward/record.url?scp=7844246144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844246144&partnerID=8YFLogxK

M3 - Article

C2 - 9814872

AN - SCOPUS:7844246144

VL - 12

SP - 2031

EP - 2039

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 15

ER -